1368563-96-5

Basic information

• Product Name: 6-(4-chloro-phenyl)-pyrimidine-4-carboxylic acid
• Synonyms: 6-(4-chloro-phenyl)-pyrimidine-4-carboxylic acid
• CAS NO: 1368563-96-5
• Molecular Weight: 234.642
• Mol File: 1368563-96-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 6-(4-chloro-phenyl)-pyrimidine-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4-chloro-phenyl)-pyrimidine-4-carboxylic acid(1368563-96-5)
• EPA Substance Registry System: 6-(4-chloro-phenyl)-pyrimidine-4-carboxylic acid(1368563-96-5)

Safety Data

• Hazardous Substances Data: 1368563-96-5(Hazardous Substances Data)

Upstream product

• 99-91-2 para-chloroacetophenone 
• 28587-05-5 3-dimethylamino-1(4-chloro-phenyl)-2-propen-1-one 
• 458541-37-2 4-(4-chlorophenyl)-pyrimidine 
• 897445-45-3 4-chloro-6-(4-chlorophenyl)pyrimidine 
• 1679-18-1 4-Chlorophenylboronic acid 

Relevant articles and documents

Synthesis, activity and docking studies of phenylpyrimidine–carboxamide Sorafenib derivatives

Two series of Sorafenib derivatives bearing phenylpyrimidine–carboxamide moiety (16a–g and 17a–p) were designed, synthesized and evaluated for the IC50values against three cancer cell lines (A549, MCF-7 and PC-3). Two selected compounds (17f and 17n) were further evaluated for the activity against VEGFR2/KDR kinase. More than half of the synthesized compounds showed moderate to excellent activity against three cancer cell lines. Compound 17f showed equal activity to Sorafenib against MCF-7 cell line, with the IC50values of 6.35 ± 0.43 μM. Meanwhile, compound 17n revealed more active than Sorafenib against A549 cell line, with the IC50values of 3.39 ± 0.37 μM. Structure–activity relationships (SARs) and docking studies indicated that the second series (17a–p) showed more active than the first series (16a–g). What's more, the introduction of fluoro atom to the phenoxy part played no significant impact on activity. In addition, the presence of electron-donating on aryl group was benefit for the activity.

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntingtons disease

We report on the development of a series of pyrimidine carboxylic acids that are potent and selective inhibitors of kynurenine monooxygenase and competitive for kynurenine. We describe the SAR for this novel series and report on their inhibition of KMO activity in biochemical and cellular assays and their selectivity against other kynurenine pathway enzymes. We describe the optimization process that led to the identification of a program lead compound with a suitable ADME/PK profile for therapeutic development. We demonstrate that systemic inhibition of KMO in vivo with this lead compound provides pharmacodynamic evidence for modulation of kynurenine pathway metabolites both in the periphery and in the central nervous system.